Novel modalities and the regulatory pathways to clear their journey to patients are driving developments in rare disease treatments in 2025. In this episode of the Drug Solutions podcast, Patrick Lavery, editor for Pharmaceutical Technology®, Pharmaceutical Technology EuropeTM, and BioPharm International®, gathers perspectives from three key opinion leaders across the industry about advancements in oncology and other areas, and the increasing role of patients' families in accelerating R&D.
All content for Drug Solutions is the property of Pharm Tech and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Novel modalities and the regulatory pathways to clear their journey to patients are driving developments in rare disease treatments in 2025. In this episode of the Drug Solutions podcast, Patrick Lavery, editor for Pharmaceutical Technology®, Pharmaceutical Technology EuropeTM, and BioPharm International®, gathers perspectives from three key opinion leaders across the industry about advancements in oncology and other areas, and the increasing role of patients' families in accelerating R&D.
Sustainability has been a recent focus of both pharmaceutical companies and stakeholders. In this episode of the Drug Solutions podcast, Patrick Lavery, editor for Pharmaceutical Technology®, Pharmaceutical Technology EuropeTM, and BioPharm International®, gathers perspectives from five key opinion leaders across the industry about a variety of applications and equipment, and provides a look into how sustainable practices can be continued and improved upon in the years to come.
Drug Solutions
Novel modalities and the regulatory pathways to clear their journey to patients are driving developments in rare disease treatments in 2025. In this episode of the Drug Solutions podcast, Patrick Lavery, editor for Pharmaceutical Technology®, Pharmaceutical Technology EuropeTM, and BioPharm International®, gathers perspectives from three key opinion leaders across the industry about advancements in oncology and other areas, and the increasing role of patients' families in accelerating R&D.
